A phase 1b clinical trial optimizing regulatory T cell depletion in combination with platinum-based chemotherapy in thoracic cancers-Reference-Cited by-同舟云学术

A phase 1b clinical trial optimizing regulatory T cell depletion in combination with platinum-based chemotherapy in thoracic cancers

Published:2021-02-09 Issue:5 Volume:21 Page:465-474
ISSN:1473-7140
Container-title:Expert Review of Anticancer Therapy
language:en
Short-container-title:Expert Review of Anticancer Therapy

Author:

Cook Alistair M.¹²^ORCID,McDonnell Alison¹²^ORCID,Millward Michael J¹³,Creaney Jenette¹²^ORCID,Hasani Arman³,McMullen Michelle³,Meniawy Tarek¹²³^ORCID,Robinson Bruce W.S.¹²⁴,Lake Richard a¹²^ORCID,Nowak Anna K.¹²³⁵^ORCID

Affiliation:

1. Medical School, Faculty of Health and Medical Sciences, University of Western Australia, Crawley, Australia

2. National Centre for Asbestos Related Diseases, University of Western Australia, Crawley, Australia

3. Department of Medical Oncology, Sir Charles Gairdner Hospital, Nedlands, Australia

4. Department of Respiratory Medicine, Sir Charles Gairdner Hospital, Nedlands, Australia

5. Department of Nuclear Medicine, Sir Charles Gairdner Hospital, Nedlands, Australia

Funder

National Health and Medical Research Council of Australia

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Oncology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737140.2021.1882308

Reference38 articles.

1. Cyclophosphamide and cancer: golden anniversary

2. Immune-Potentiating Effects of the Chemotherapeutic Drug Cyclophosphamide

3. Cyclophosphamide-sensitive T lymphocytes suppress the in vivo generation of antigen-specific cytotoxic T lymphocytes

4. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells.

5. Immunotherapy and chemotherapy — a practical partnership

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tumor-Targeted Nonablative Radiation Promotes Solid Tumor CAR T-cell Therapy Efficacy;Cancer Immunology Research;2023-08-04